IDH1 and acute myeloid leukemia: AG-120 (Ivosidenib), an optimized compound from AGI-5198, is an FDA-approved oral administration drug that can effectively reduce the intracellular D-2-HG and induce IDH1 R132H and IDH1 R132C mutated cancer cell differentiation in AML murine xenograft models [136].